CClinicalTrials.gg
CompletedNCT02067247Updated Nov 19, 2014

Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease

An interventional study of BeamMed Speed-of-Sound bone strength test at forearm in Gaucher Disease Type 1, sponsored by Shaare Zedek Medical Center. Completed at 1 site in Israel. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-19.

Sponsored by Shaare Zedek Medical Center · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the accuracy and comparability and secondarily to assess the values achieved by measurement of the forearm BMD by DXA and SOS by BeamMed, relative to standard DXA evaluations at the FN and LS.

Read the detailed description

Dual-energy X-ray absorptiometry (DXA) is the current gold standard for the clinical diagnosis of osteoporosis based on measurement of bone mineral density (BMD) [Baim et al, 2006]. As DXA technology continues to evolve, new instruments and technologies are introduced [Shepherd et al, 2005], making it necessary to document how these advances compare to prior densitometers.

The purpose of this study is to assess bone mineral density (BMD) comparability and precision using a standard Hologic DXA unit and the quantitative ultrasound-driven speed-of-sound (SOS) BeamMed technology. The physical and mechanical properties of bone that are measured by SOS are different than bone density measured by DXA and reflect bone strength and elasticity [Goossens et al, 2008]. The cohorts will be patients with Gaucher disease [Zimran \& Elstein, 2010] who currently are requested to undergo BMD evaluation only bi-annually [Mistry et al, 2011], partly because of the radiation of DXA scans (admittedly low relative to standard X-rays and CT). Patients with Gaucher disease are at added risk for osteonecrosis and pathological fractures but to date no biomarker or technology has been able to predict which patients are imminently at risk. Because the option of disease-specific but very costly enzyme replacement therapy (ERT) [Barton et al, 1991] is predicating on the estimated risk of severe disease, predicting skeletal damage (especially osteonecrosis at the femoral neck, FN) because of osteopenia or osteoporosis has clinically relevant ramifications [Mistry et al, 2011]. Additionally, it has been shown that there is a correlation between low BMD at the lumbar spine (LS) and anemia in patients with Gaucher disease [Khan et al, 2012], so that with correction of anemia with ERT it is hoped that there will be amelioration of BMD values, and this too would be worth performing at closer intervals.

The least inconvenient and shortest evaluation for BMD is at the forearm. For approximately a year, all patients at the Gaucher disease have had DXA forearm evaluations when undergoing routine testing. It is the intention of this study to prospectively compare forearm SOS results [Olszynski et al, 2013] with those from the standard DXA equipment with the possibility of using SOS as a quantitative measure of bone integrity on a more regular basis.

The strategy will be to measure forearm BMD by DXA and SOS by BeamMed for comparison of accuracy and comparability and secondarily to assess the values achieved at the forearm relative to standard DXA evaluations at the FN and LS.

Patients who arrive at the Gaucher Clinic for routine monitoring that includes DXA evaluation of BMD at FN, LS, and forearm will be requested to consent to undergo SunBeam evaluation at the forearm as well. The same DXA hardware and software (Hologic, Bedford, MA) will be used for all examinations as have been employed by the Gaucher Clinic since August 2011.

The SOS technology as developed by the BeamMed Company (originally, the Sunlight Ultrasound Technologies, Israel) is based on the physical property that ultrasound waves travel faster through bone than soft tissue. The bone sonometer measures the time that elapses between the axially transmitted sound generated as an inaudible high-frequency pulsed acoustic signal at a center frequency of 1.25 MHz and the first reception of a signal after it has traveled through the selected bone. This is recorded as the SOS in m/sec. The ultrasonic waves are transmitted and received by transducers embedded in the ultrasound probe. As the ultrasound wave travels, the speed, dispersion, and attenuation of the signal is influenced by the density, elasticity, and cohesiveness of the medium, so that the greater the density and elasticity of the medium, the faster the speed of propagation [Ashman et al, 1984].

The device consists of a desktop main unit and 3 probes of different sizes. The small probe (1.4cm x 2.7cm x 11cm), 900-1000 KHz will be used for this study. Calibration is performed each day using a standardized calibrating plastic provided by the company. The SOS is determined as the mean of 3 scans that are found to be statistically similar (coefficient of variation below 1.2%), as calculated by the software provided with the device. Based on these 3 readings, the 95th percentile of the measured SOS is determined and used for statistical analysis.

02

Conditions studied

  • Gaucher Disease Type 1

Browse trials for

03

In context

Gaucher Disease

171 studies on the registry are indexed under Gaucher Disease; 37 are open to participants now.

This study's enrollment of 100 is above the median of 20 across 98 interventional studies indexed under Gaucher Disease.

Browse Gaucher Disease studies →

Lead sponsor

Shaare Zedek Medical Center is the lead sponsor of 191 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age: >18
  • Gaucher disease type 1
  • Able to undergo a DEXA test

Exclusion criteria

Exclusion Criteria:

  • Minors
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    SOS forearm test

    BeamMed Speed-of-Sound bone strength test at forearm

    Device: BeamMed Speed-of-Sound bone strength test at forearm

Interventions

  • DeviceBeamMed Speed-of-Sound bone strength test at forearm

    BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test

    Also known as: OMNISENSE 7000S ULTRASOUND BONE SONOMETER

06

What researchers measure

Primary outcomes

  1. BMD measurements by DEXA and SOS

    Time frame: 6 months

Secondary outcomes

  1. T-score and Z-score by DEXA and SOS

    Time frame: 6 months

07

Study locations

1 site
  • Shaare Zedek Medical Center
    Jerusalem, Israel
08

References and documents

Publications

  • Baskin E, Dinur T, Lebel E, Tiomkin M, Elstein D, Zimran A. Comparison of Bone Mineral Density by Dual-Energy X-Ray Absorptiometry and Bone Strength by Speed-of-Sound Ultrasonography in Adults With Gaucher Disease. J Clin Densitom. 2016 Oct;19(4):465-470. doi: 10.1016/j.jocd.2015.12.002. Epub 2016 Jan 15. PubMed 26781431 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02067247
Lead sponsor
Shaare Zedek Medical Center
Responsible party
Ari Zimran (Prof., Shaare Zedek Medical Center) — Principal investigator
First posted
Feb 20, 2014
Start date
Feb 2014
Primary completion
Sep 2014
Completion
Sep 2014
Last update
Nov 19, 2014

Study contacts

Ari Zimran, Prof.
principal investigator · Shaare Zedek Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion